More research needs to be done to figure out the underlying molecular mechanism of mutations of the KEAP1/NFE2L2/CUL3 pathway in lung adenocarcinoma, and there is still a long way to go to target these mutations as a new therapeutic strategy. This evidence concerns the gene NFE2L2 and lung adenocarcinoma.